Cardiac Biomarkers Market Players, Share, Size, Trend, Segment Analysis and Forecast to 2032

 Cardiac Biomarkers Market

The key factors that drive the cardiac biomarkers market are the increasing prevalence of cardiovascular diseases and lifestyle diseases, increasing prevalence of cardiovascular diseases and lifestyle diseases, increase in demand for disease-specific treatment & research in which cardiac biomarkers are used, technological advancements in cardiac biomarkers, and favorable government initiatives to create awareness related to cardiovascular diseases. However, a lack of awareness among people is expected to hamper market growth.

The Cardiac Biomarkers Market is expected to reach USD 11.3 Billion by 2032 at 13.7% CAGR during the forecast period 2023-2032

There are a number of factors that impact the growth of the cardiac biomarkers market. Some of the key factors include a rise in demand for diagnostic and testing of various cardiovascular diseases, development and advancement in cardiac biomarkers, and growth in the patient population suffering from cardiovascular diseases. Other key growth drivers include the rise in the number of new cardiovascular cases diagnosed each year and the increase in demand for disease-specific treatment in which cardiac biomarkers are used. The increasing prevalence of cardiovascular diseases is expected to boost the cardiac biomarkers market during the forecast period.

Major Key Players:

Some of the Cardiac Biomarkers Market Players are Novartis Ag, Quidel Corporation, ACS Biomarker B.V., Randox Laboratories Ltd., Trivitron Healthcare, F. Hoffman La Roche Ltd., Johnson & Johnson Services Inc., Abbott Laboratories, Siemens, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, and Biomérieux Sa.

Segment Analysis

The cardiac biomarkers are widely used as an integrated diagnostic approach for various cardiovascular diseases. The market has been segmented based on cardiac biomarker type - Creatine Kinase (CK-MB), Troponins T and I, myoglobin, BNPs, IMA, and others. Troponins I and T isthe highest revenue-generating segment in the overall cardiac biomarker market due to theirprodigious specificity and theirability to accurately detect the cardiac events of Acute Coronary Syndrome (ACS). It is also anticipated to exhibitthe highest growth during the forecast period.

Based on application, the market is segmented into myocardial infarction(MI), congestive heart failure, acute coronary syndrome, atherosclerosis, and others. Myocardial infarction (MI) holds the highest market share, followed by Acute Coronary Syndrome (ACS) due to the highest prevalence rate among cardiovascular diseases (CVDs). Myocardial infarction is projected to grow at the highest CAGR of 11.5% during the study period.

The location of the testing segment is classified as point-of-care testing and laboratory testing. Doctors and clinicians largely prefer point-of-care cardiac testing for rapidpatientmonitoring with chest pain in an emergency care unit, resulting inthe highest CAGR. Laboratory testing is expected to grow at a significant CAGR of 9% during the period of 2020 to 2032.

Regional Analysis

Based on region, the global cardiovascular biomarkers market is segmented into the Americas, Europe, Asia-Pacific, and MEA. The Americas leads the global market due to the high CVD prevalence rate, high demand for cardiac testing, and rising awareness aboutcardiac diagnostics solutions. Asia-Pacific is expected to register the highest CAGR due to increasing disposable incomes,modernization, and rising affordability for advanced cardiac treatments.

The Americas dominated the cardiac biomarker market in 2019 and is likely to continue to command during the assessment period. This can be attributed to the high prevalence of cardiovascular diseases & diabetes, product launch, and acquisition in this region. As per the Centers for Disease Control and Prevention, heart disease is one of the leading causes of death in the US. Around 655,000 Americans die from heart disease each year, or one person dies every 36 seconds in the US from cardiovascular disease. Heart disease costs the US about USD 219 billion each year from 2014 to 2015. Furthermore, the key players in the regional market are also focused on product development and launch to expand their product portfolio.

Asia-Pacific is anticipated to register the highest growth rate over the forecast period from 2020 to 2032. This is owing to the high incidence of cardiovascular diseases, COPD, and diabetes. As per the American Diabetes Association, more than 60% of the entire diabetic population lives in Asia. India and China are highly populated countries.

Moreover, various initiatives taken by the governments in Asia-Pacific to support the healthcare system are also fueling the regional market's growth. For instance, in August 2020, the Government of India announced a national health ID for every Indian to create a centralized mechanism to identify every participating user in the National Health Stack uniquely. Furthermore, the rising per capita disposable income of middle-class families, which accounts for a large population in Asia, results in individuals spending more on health. This is driving the growth of the cardiac biomarkers market in the region during the forecast period.

About Market Research Future

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 646 845 9312

Email: sales@marketresearchfuture.com

Comments

Post a Comment

Popular posts from this blog

Serotonin Syndrome Market, Size, Share, Growth, Business Risk & Industry Analysis Reports 2030

  Serotonin Syndrome Market The serotonin syndrome market report is an informative and in-depth analysis that offers a detailed overview of the industry, including recent developments and potential proportions of the demand for serotonin syndrome in terms of products and services.  The  Serotonin Syndrome Market  is expected to reach USD 692.2 Million by 2030 at 4.8% CAGR during the forecast period 2022-2030. Serotonin syndrome is a group of symptoms such as high body temperature, increased reflexes, anxiety, tremor, sweating, diarrhea, dilated pupils, etc. due to the use of serotonergic drugs. Severe complications, such as seizures and extensive muscle breakdown, can lead to death. The case of Libby Zion in 1984 is an example of death from serotonin syndrome. Serotonin syndrome is usually caused by a synergistic effect of two or more serotonergic drugs, commonly including serotonin norepinephrine reuptake inhibitor (SNRI), selective serotonin reuptake inhibitor (SSR...
Read more

Personalized Medicine Market, Opportunities, Size, Share, Trends Analysis and Forecast to 2032

  By 2032, the personalized medicine market is expected to be worth USD 970.7 billion, growing at a CAGR of 7.20%. The global demand for novel drugs to treat the rising incidence of cancer and other diseases is one of the factorersonalized medicine, also identifies patients who will likely benefit from specific therapy and supports long-term monitoring of how they react to that treatment. Physicians can make better choices about the most suitable treatments for their patients via companion diagnostics, and they can modify those treatments, if necessary, based on each patient's unique response, driving the development of personalized medicine market growth. Additionally, companion tests specifically created to assess a subject's suitability for a given treatment and their reaction to a prescribed course of treatment increasingly use personalized medicine in their applications. In contrast to the conventional "one size fits all" approach, personalized medicine posses...
Read more

Electric Wheelchair Market Global Synopsis, Future Scope, Top Key Players and Forecast to 2030

  Electric Wheelchair Market Electric wheelchairs get power from an electric motor that comes attached with the electric wheelchair. These wheelchairs offer great mobility and are light in weight. These are very compact in size and can be used in narrow pathways. The global electric wheelchair market is expecting substantial market growth during the forecast period (2019-2023). Market Research Future (MRFR) made a claim recently that the global electric wheelchair market can surpass the existing market valuation with relative ease. Electric Wheelchair Market  size is expected to reach USD 6.47 Billion by 2030 at 6.8% CAGR during the forecast period 2022-2030. The electric wheelchair market is expecting strong support from various pointers for a better market growth. It is expecting strong growth due to competitors participating more and more in the market to take the market ahead with their strategic moves. Its easy application is fast gaining momentum. Latest innovations are ...
Read more